This takes Halasz’s Total direct and indirect holding to 27.3 million shares.
Total consideration for the 400,000 shares purchased amounted to $11,600 for an average price of $0.029.
Cellmid has two business segments, consumer health and its midkine (MK) portfolio.
The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.
Cellmid aims to follow in the footsteps of FGF5 by commercialising its MK portfolio.
Cellmid recorded a 79% increase in December quarter hair loss product sales compared with the prior December quarter and will enter 2017 with a healthy $5.3 million in cash.